The compound PMD-026 is the first RSK inhibitor undergoing clinical trial in the US in patients with metastatic and triple-negative breast cancer, and the trial is currently ongoing (NCT04115306). The gene discussed is RPS6KA3; the disease is triple-negative breast carcinoma.